New Vaccine Shows Promise for Cancer Patients
An initial trial demonstrated that an experimental vaccine targeting the "Keras" genetic mutation in pancreatic cancer is effective and safe. It successfully stimulated the immune system in 90% of participants and protected them from infection or disease progression for more than a year and a half. The results showed that the vaccine, called "M. Keras-Vax," caused only mild or moderate side effects. Its aim is to prevent pancreatic cancer by destroying cells carrying the mutation before they transform into malignant tumors. This study represents a first step toward developing preventive vaccines against pancreatic cancer, although the current results do not establish definitive protection. The vaccine is now being tested on other groups of high-risk patients.
Notice: This Is an AI-Generated Summary
Comments (0)